Correlation of the clinical progression with the degree and pattern of atrophy in patients with multiple sclerosis treated cladribine tablets

被引：0
|
作者：
Pogoda-Wesolowska, Aleksandra [1 ]
Aftyka, Joanna [2 ]
Zegadlo, Arkadiusz [3 ]
Staszewski, Jacek [1 ]
Stepien, Adam [1 ]
机构：
[1] Mil Inst Med, Natl Res Inst, Neurol Clin, Warsaw, Poland
[2] Warsaw Univ Technol, Fac Phys, Warsaw, Poland
[3] Mil Inst Med, Natl Res Inst, Dept Med Radiol, Warsaw, Poland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1871/4301
引用
收藏
页码：1252 / 1253
页数：2
相关论文
共 50 条
  • [31] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
    Cook, Stuart D.
    Giovannoni, Gavin
    Leist, Thomas P.
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 54 - 55
  • [32] Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
    Cook, Stuart
    Leist, Thomas
    Comi, Giancarlo
    Montalban, Xavier
    Giovannoni, Gavin
    Nolting, Axel
    Hicking, Christine
    Galazka, Andrew
    Sylvester, Elke
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 29 : 157 - 167
  • [33] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, Stuart
    Giovannoni, Gavin
    Leist, Thomas
    Syed, Sana
    Nolting, Axel
    Damian, Doris
    Schick, Regina
    NEUROLOGY, 2019, 92 (15)
  • [34] Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 465 - 466
  • [35] Long-term experience with cladribine tablets in multiple sclerosis patients
    Oreja-Guevara, Celia
    Gomez Estevez, Irene
    Garcia Vasco, Lorena
    Quezada Sanchez, Johnny
    Diaz, Judit
    Gil-Perotin, Sara Garcia
    Alba Suarez, Elda Maria
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 966 - 966
  • [36] Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis
    Cook, S.
    Giovannoni, G.
    Leist, T.
    King, J.
    Syed, S.
    Nolting, A.
    Schick, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 469 - 469
  • [37] Positive impact of cladribine tablets on reducing brain atrophy in patients with relapsing-remitting multiple sclerosis: A longitudinal study
    Achiron, Anat
    Warszawer, Yehuda
    Nissan, Yael
    Kerpel, Ariel
    Hoffmann, Chen
    Harari, Gil
    Magalashvili, David
    Tal, Sigal
    MULTIPLE SCLEROSIS JOURNAL, 2025,
  • [38] Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis
    Viglietta, V.
    Greenberg, S.
    Mikol, D.
    Weiner, J.
    Alteri, E.
    Chang, P.
    Krumwieh, D.
    Musch, B.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S126 - S126
  • [39] Late stage clinical development plan for cladribine tablets in the treatment of multiple sclerosis
    Viglietta, V.
    Greenberg, S.
    Mikol, D.
    Weiner, J.
    Alteri, E.
    Chang, P.
    Krumwieh, D.
    Musch, B.
    JOURNAL OF NEUROLOGY, 2010, 257 : S143 - S144
  • [40] An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis (RMS)
    Galazka, A.
    Nolting, A.
    Cook, S.
    Leist, T.
    Comi, G.
    Montalban, X.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 999 - 1000
12345